查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1595116

骨质疏鬆症药物市场：按药物类型、给药途径和应用分类 - 全球预测 2025-2030

Osteoporosis Drugs Market by Drug Type (Bisphosphonates, Calcitonin, Parathyroid Hormone Therapy), Route of Administration (Injectable, Oral), Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年骨质疏鬆药物市值为83.2亿美元，预计2024年将达87.7亿美元，复合年增长率为5.60%，到2030年将达到121.9亿美元。

骨质疏鬆症药物市场专注于骨质疏鬆症的治疗和预防，骨质疏鬆症是一种以骨量减少和骨折风险增加为特征的疾病。该市场包括多种药物治疗，包括双磷酸盐、选择性雌激素受体调节（SERM）、副甲状腺素（PTH）类似物和单株抗体。世界人口老化推动了对这些药物的需求，尤其是停经后女性，骨质疏鬆症的治疗可以提高生活品质并降低与骨折治疗相关的医疗费用。应用范围横跨医院、诊所和居家医疗，涵盖治疗和预防。最终使用者主要是老年人，尤其是超过闭经的女性。

主要市场统计
基准年[2023] 83.2亿美元
预测年份 [2024] 87.7亿美元
预测年份 [2030] 121.9亿美元
复合年增长率（%） 5.60%

影响市场成长的关键因素包括提高意识和诊断率、药物处方和管理的进步以及支持政府医疗保健政策。医疗基础设施正在迅速改善的新兴市场也存在机会。开发副作用较少、给药方案较简单的药物具有巨大的潜力。然而，它也存在很大的局限性，包括高昂的药物成本、严格的法律规范以及抑制患者依从性的潜在副作用。另一个挑战是医疗政策和报销问题因地区而异。

提供成长机会的创新研发领域包括联合治疗的开发、个人化医疗方法以及远距患者管理的远距远端医疗整合。生物技术和基因治疗的进步有望成为新的治疗平台。该市场表现出竞争性，主要企业大力投资研究，以减少现有药物的副作用并提高其有效性。鼓励公司专注于研发策略联盟和合作，开拓开拓的区域市场，并强调病患教育计画以提高市场渗透率。市场扩张也应优先考虑解决现有的限制，例如优化给药系统和提高製剂的安全性。

市场动态：揭示快速发展的骨质疏鬆症药物市场的关键市场洞察

供需因素的动态交互作用正在改变骨质疏鬆药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 老年人口的增长和生活方式的改变影响骨骼健康
    • 提高停经后妇女对骨质疏鬆症照护和骨质疏鬆症盛行率的认识
  • 市场限制因素
    • 骨质疏鬆治疗药物专利到期的担忧
  • 市场机会
    • 活性化医疗机构的产品开发和研究活动
    • 各机构研究经费快速增加
  • 市场挑战
    • 与骨质疏鬆症药物相关的副作用，如噁心、胃灼热和溃疡

波特的五力策略工具驾驭骨质疏鬆症药物市场

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解骨质疏鬆药物市场的外部影响

外部宏观环境因素在塑造骨质疏鬆药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解骨质疏鬆症治疗药物市场的竞争状况

对骨质疏鬆症药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵骨质疏鬆药物市场供应商绩效评估

FPNV定位矩阵是评估骨质疏鬆药物市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘骨质疏鬆症药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，骨质疏鬆症治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 老年人口的增加和生活习惯的改变正在影响骨骼健康
      • 意识提升停经后妇女骨质疏鬆症照护和骨质疏鬆症发生率的意识
    • 抑制因素
      • 对骨质疏鬆症药物专利到期的担忧
    • 机会
      • 医疗机构的新产品开发和研究活动
      • 各组织增加研究经费
    • 任务
      • 与骨质疏鬆症药物相关的副作用，如噁心、胃灼热和溃疡
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章：依药物类型分類的骨质疏鬆症治疗市场

  • 双磷酸盐
  • 抑钙素
  • 副甲状腺素治疗
  • 活化因数配体抑制剂
  • 选择性雌激素抑制剂调变器

第七章骨质疏鬆症治疗药物市场：依给药途径

  • 可注射的
  • 口服

第八章骨质疏鬆症治疗药物市场：依应用分类

  • 原发性骨质疏鬆症
  • 续发性骨质疏鬆症

第九章 北美及南美骨质疏鬆药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区骨质疏鬆药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲骨质疏鬆药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 宣布为骨质疏鬆症研究提供新资金
    • 世卫组织和欧洲骨质疏鬆症协会宣布达成合作协议，以帮助预防全球骨质疏鬆症和骨折。
    • FDA核准Timlos 用于治疗男性骨质疏鬆症
    • Evenity（romosozumab）治疗骨折高风险停经后妇女的严重骨质疏鬆症获得了 CHMP 的正面意见
    • 安进 (Amgen) 以 278 亿美元收购 Horizo​​n，以扩大罕见疾病产品线。
    • 中外製药与东和製药推出骨质疏鬆症治疗药物“Edirol片”
    • Akums Drugs 与 Microcore Research 合作生产 NESM补充品。
    • Lupin 已与 Irom 达成协议，在日本进行停经后治疗药物的临床试验和销售。
    • Farmanovia 收购罗氏 Rocaltrol 拓展中国业务
    • Timros 製造商 Radius Health 以 8.9 亿美元的价格出售给投资公司。
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Alembic Pharmaceuticals Ltd.
  • Alkem Laboratories Ltd.
  • Amgen, Inc.
  • Apotex Inc.
  • Century Pharmaceuticals Ltd.
  • Cipla Ltd.
  • Cubit Healthcare
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • F.Hoffmann La Roche AG
  • GlaxoSmithKline PLC
  • Hetero Healthcare Ltd.
  • Intas Pharmaceuticals Ltd
  • Macleods Pharmaceuticals Ltd.
  • Merck & Co AG
  • Midas Pharma GmbH
  • Mylan NV by Viatris Inc.
  • Natco Pharma Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Polpharma
  • Pulse Pharmaceuticals
  • Steris Healthcare Pvt. Ltd.
  • Sun Pharmaceutical Industries Ltd
  • Taj Pharmaceuticals Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Vintage Labs Pvt. Ltd.
Product Code: MRR-AD36CD8980EF

The Osteoporosis Drugs Market was valued at USD 8.32 billion in 2023, expected to reach USD 8.77 billion in 2024, and is projected to grow at a CAGR of 5.60%, to USD 12.19 billion by 2030.

The market for osteoporosis drugs is primarily focused on the treatment and prevention of osteoporosis, a condition characterized by reduced bone mass and increased fracture risk. This market encompasses a variety of pharmaceutical treatments, including bisphosphonates, selective estrogen receptor modulators (SERMs), parathyroid hormone (PTH) analogs, and monoclonal antibodies. The necessity for these drugs is driven by the global aging population, notably among post-menopausal women, making the treatment of osteoporosis critical for improving quality of life and reducing healthcare costs related to fracture treatment. Application extends across hospitals, clinics, and home healthcare settings, targeting both therapeutic and preventive care. The end-users predominantly are older adults, particularly women beyond the menopausal age.

KEY MARKET STATISTICS
Base Year [2023] USD 8.32 billion
Estimated Year [2024] USD 8.77 billion
Forecast Year [2030] USD 12.19 billion
CAGR (%) 5.60%

Key factors influencing market growth include increasing awareness and diagnosis rates, advances in drug formulation and administration, and supportive government healthcare policies. Opportunities also lie in emerging markets where healthcare infrastructure is rapidly improving. The development of drugs with fewer side effects and more convenient dosing regimens presents significant potential. However, significant limitations include high drug costs, stringent regulatory frameworks, and potential side effects that may impede patient adherence. Additionally, varying healthcare policies and reimbursement issues across regions pose challenges.

Innovation and research areas offering growth opportunities include the development of combination therapies, personalized medicine approaches, and the integration of telemedicine for remote patient management. Advances in biotechnology and gene therapy hold the promise of novel treatment platforms. The market exhibits a competitive nature with prominent players investing heavily in research to mitigate the existing drug side effects and improve efficacy. Companies are recommended to focus on strategic alliances and collaborations for R&D, exploring untapped regional markets, and emphasizing patient education programs to enhance market penetration. Addressing the existing limitations by optimizing drug delivery systems and enhancing drug formulation safety profiles should also be prioritized to bolster market expansion.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Osteoporosis Drugs Market

The Osteoporosis Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising elderly population coupled with changing lifestyle habits impacting bone health
    • Increasing awareness of osteoporosis care and incidence of osteoporosis in postmenopausal women
  • Market Restraints
    • Concerns over patent expiration of osteoporosis drugs
  • Market Opportunities
    • Emerging product development and research activities in healthcare organizations
    • Proliferation in the research funding from various organizations
  • Market Challenges
    • Side effects such as nausea, heartburn, and ulcers associated with osteoporosis drugs

Porter's Five Forces: A Strategic Tool for Navigating the Osteoporosis Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Osteoporosis Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Osteoporosis Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Osteoporosis Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Osteoporosis Drugs Market

A detailed market share analysis in the Osteoporosis Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Osteoporosis Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Osteoporosis Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Osteoporosis Drugs Market

A strategic analysis of the Osteoporosis Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Osteoporosis Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alembic Pharmaceuticals Ltd., Alkem Laboratories Ltd., Amgen, Inc., Apotex Inc., Century Pharmaceuticals Ltd., Cipla Ltd., Cubit Healthcare, Dr. Reddy's Laboratories, Eli Lilly and Company, F.Hoffmann La Roche AG, GlaxoSmithKline PLC, Hetero Healthcare Ltd., Intas Pharmaceuticals Ltd, Macleods Pharmaceuticals Ltd., Merck & Co AG, Midas Pharma GmbH, Mylan N.V. by Viatris Inc., Natco Pharma Ltd., Novartis AG, Pfizer Inc., Polpharma, Pulse Pharmaceuticals, Steris Healthcare Pvt. Ltd., Sun Pharmaceutical Industries Ltd, Taj Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., and Vintage Labs Pvt. Ltd..

Market Segmentation & Coverage

This research report categorizes the Osteoporosis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Bisphosphonates, Calcitonin, Parathyroid Hormone Therapy, Rank Ligand Inhibitors, and Selective Estrogen Inhibitors Modulator.
  • Based on Route of Administration, market is studied across Injectable and Oral.
  • Based on Application, market is studied across Primary Osteoporosis and Secondary Osteoporosis.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising elderly population coupled with changing lifestyle habits impacting bone health
      • 5.1.1.2. Increasing awareness of osteoporosis care and incidence of osteoporosis in postmenopausal women
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns over patent expiration of osteoporosis drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging product development and research activities in healthcare organizations
      • 5.1.3.2. Proliferation in the research funding from various organizations
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects such as nausea, heartburn, and ulcers associated with osteoporosis drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Osteoporosis Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Bisphosphonates
  • 6.3. Calcitonin
  • 6.4. Parathyroid Hormone Therapy
  • 6.5. Rank Ligand Inhibitors
  • 6.6. Selective Estrogen Inhibitors Modulator

7. Osteoporosis Drugs Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral

8. Osteoporosis Drugs Market, by Application

  • 8.1. Introduction
  • 8.2. Primary Osteoporosis
  • 8.3. Secondary Osteoporosis

9. Americas Osteoporosis Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Osteoporosis Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Osteoporosis Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. New funding for osteoporosis research announced
    • 12.3.2. WHO and ESCEO announce collaborative agreement to benefit global osteoporosis and fracture prevention.
    • 12.3.3. FDA Clears Tymlos for Osteoporosis in Men
    • 12.3.4. EVENITY (romosozumab) Receives Positive CHMP Opinion for the Treatment of Severe Osteoporosis in Postmenopausal Women at High Risk of Fracture
    • 12.3.5. Amgen to Acquire Horizon for USD 27.8 Billion, Expanding Rare Disease Pipeline.
    • 12.3.6. Chugai and Towa Launch Edirol Tablet for Osteoporosis Treatment
    • 12.3.7. Akums Drugs ties up with Microcore Research to manufacture NESM supplements.
    • 12.3.8. Lupin signs agreement with I'rom for clinical trials and marketing of post-menopause drug in Japan.
    • 12.3.9. Pharmanovia expands its footprint in China with the acquisition of Rocaltrol from Roche
    • 12.3.10. Tymlos maker Radius Health sells itself to investment firms for USD 890 Million..
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alembic Pharmaceuticals Ltd.
  • 3. Alkem Laboratories Ltd.
  • 4. Amgen, Inc.
  • 5. Apotex Inc.
  • 6. Century Pharmaceuticals Ltd.
  • 7. Cipla Ltd.
  • 8. Cubit Healthcare
  • 9. Dr. Reddy's Laboratories
  • 10. Eli Lilly and Company
  • 11. F.Hoffmann La Roche AG
  • 12. GlaxoSmithKline PLC
  • 13. Hetero Healthcare Ltd.
  • 14. Intas Pharmaceuticals Ltd
  • 15. Macleods Pharmaceuticals Ltd.
  • 16. Merck & Co AG
  • 17. Midas Pharma GmbH
  • 18. Mylan N.V. by Viatris Inc.
  • 19. Natco Pharma Ltd.
  • 20. Novartis AG
  • 21. Pfizer Inc.
  • 22. Polpharma
  • 23. Pulse Pharmaceuticals
  • 24. Steris Healthcare Pvt. Ltd.
  • 25. Sun Pharmaceutical Industries Ltd
  • 26. Taj Pharmaceuticals Ltd.
  • 27. Teva Pharmaceutical Industries Ltd.
  • 28. Vintage Labs Pvt. Ltd.

LIST OF FIGURES

  • FIGURE 1. OSTEOPOROSIS DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. OSTEOPOROSIS DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. OSTEOPOROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. OSTEOPOROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. OSTEOPOROSIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. OSTEOPOROSIS DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY CALCITONIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY PARATHYROID HORMONE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY RANK LIGAND INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY SELECTIVE ESTROGEN INHIBITORS MODULATOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY PRIMARY OSTEOPOROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY SECONDARY OSTEOPOROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. OSTEOPOROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. OSTEOPOROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023